# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: K120986   
B. Purpose for Submission: New device   
C. Measurand: Anti- JC Virus (JCV) antibodies   
D. Type of Test: Enzyme Linked Immunosorbent Assay (ELISA)   
E. Applicant: Focus Diagnostics Inc.   
F. Proprietary and Established Names: STRATIFY $\scriptstyle { \mathrm { J C V } _ { \mathbb { R } } }$ DxSelect™

# G. Regulatory Information:

1. Regulation section: 21 CFR 866.3336: John Cunningham Virus serological reagents

2. Classification: Class II Special Controls

3. Product code: OYP

4. Panel: Microbiology (83)

# H. Intended Use:

1. Intended use(s):

The Focus Diagnostics’ STRATIFY JCV $^ \mathrm { \textregistered }$ DxSelect™ assay is intended for the qualitative detection of antibodies to JC virus in human serum or plasma. The assay is intended for use in conjunction with other clinical data, in multiple sclerosis patients receiving or considering natalizumab therapy, as an aid in risk stratification for progressive multifocal leukoencephalopathy development. The assay is for professional use only.

The assay is not intended for donor screening. The performance of this assay has not been established for use in other immunocompromised patient populations or patients with different disease conditions or undergoing other treatments or in neonates and pediatric patient populations.

2. Indication(s) for use: The same as intended use

3. Special conditions for use statement(s): For prescription use only

4. Special instrument requirements: None

# I. Device Description:

The Focus Diagnostics’ STRATIFY $\small \mathrm { J C V _ { \mathbb { R } } }$ DxSelect™ consists of two devices. The first is an initial detection ELISA and the second device is a confirmatory (inhibition) ELISA. Both tests utilize the same recombinant antigen which is used in two different formats as described in section L. The devices include the following reagents; Recombinant JC virus like particles (VLP), a JCV high and low positive controls, consisting of human sera that is positive for JCV antibodies, and JCV negative control consisting of human sera that is negative for JCV antibodies. The conjugate, substrate, wash buffers, and blocking buffers needed for the test are not supplied with the device and are listed together with other reagents and consumables in the device labeling.

# J. Substantial Equivalence Information:

1. Predicate device name(s): STRATIFY JCV™ Antibody ELISA

2. Predicate 510(k) number(s): K112394

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>The assay is intended forthe qualitative detection ofantibodies to JC virus inhuman serum or plasma.</td><td rowspan=1 colspan=1>Same.</td></tr><tr><td rowspan=1 colspan=1>Measurand</td><td rowspan=1 colspan=1>Anti-JCV antibodies</td><td rowspan=1 colspan=1>Same.</td></tr><tr><td rowspan=1 colspan=1>Technology</td><td rowspan=1 colspan=1>Detection ELISA with asecondary ConfirmationELISA for specimens thathave results in theindeterminate zone levels.</td><td rowspan=1 colspan=1>Same.</td></tr><tr><td rowspan=1 colspan=1>Matrix (sample type)</td><td rowspan=1 colspan=1>Serum and Plasma</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=3 colspan=1>Indications for use</td><td rowspan=1 colspan=1>The assay is intended foruse in conjunction withother clinical data, inmultiple sclerosis patientsreceiving or considering</td><td rowspan=3 colspan=1>The assay is intended foruse in conjunction withother clinical data, inmultiple sclerosis andCrohn&#x27;s disease patientsreceiving natalizumabtherapy, as an aid in riskstratification forprogressive multifocalleukoencephalopathydevelopment. The assay isfor professional use onlyand is to be performedonly at FocusDiagnostics&#x27; ReferenceLaboratory.The assay is not intendedfor donor screening. Theperformance of this assayhas not been establishedfor use in otherimmunocompromisedpatient populations or inneonates and pediatricspatient populations</td></tr><tr><td rowspan=1 colspan=1>natalizumab therapy, as</td></tr><tr><td rowspan=1 colspan=1>an aid in risk stratificationfor progressive multifocalleukoencephalopathydevelopment. The assay isfor professional use only.The assay is not intendedfor donor screening. Theperformance of this assayhas not been establishedfor use in otherimmunocompromisedpatient populations or inneonates and pediatricpatient populations.</td></tr><tr><td rowspan=2 colspan=1>Assay Cut-off points</td><td rowspan=1 colspan=1>Index &lt; 0.2, negative</td><td rowspan=1 colspan=1>nOD &lt; 0.1, negative</td></tr><tr><td rowspan=1 colspan=1>Index ≥ 0.4, positive</td><td rowspan=1 colspan=1>nOD ≥ 0.2, positive</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI EP05-A2; Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline $2 ^ { \mathrm { n d } }$ Edition (2004).

CLSI EP07-A2; Interference Testing in Clinical Chemistry; Approved Guideline $2 ^ { \mathrm { n d } }$ Edition (2005).

CLSI H18-A4; Procedures for the Handling and Processing of Blood Specimens;   
Approved Guideline $4 ^ { \mathrm { t h } }$ Edition (2010).

# L. Test Principle:

In the Focus Diagnostics’ STRATIFY $\small \mathrm { J C V _ { \mathbb { R } } }$ DxSelect™ test, JC virus-like particles (VLP) are pre-coated onto 96-well microtiter plates. Diluted serum or plasma specimens and controls are incubated in the wells to allow JCV-specific antibodies present in the specimens to react with the JC VLP antigen. Nonspecific reactants are removed by washing. Peroxidaseconjugated anti-human antibodies are added to react with JCV-specific antibodies. Excess conjugate is removed by washing. Enzyme substrate and chromogen are added, and the color is allowed to develop. After adding the Stop Reagent, the resultant color change is quantified by a spectrophotometric reading of optical density (OD). Specimen OD readings are compared with Cut-Off Calibrator OD readings to determine results. Each specimen result is reported as an index value. A specimen with an index value that is greater than a specified upper cut-off is reported as positive for detectable JCV-specific antibodies, whereas a specimen with an index value less than the specified lower cut-off is reported as negative for detectable JCV-specific antibodies. A specimen with an index value that is equal to or between the upper and lower cut-off values is reported as indeterminate. An indeterminate result requires further evaluation in the confirmation (inhibition) assay.

In the confirmation assay, soluble JC VLP antigen will compete with plate bound JC VLP antigen for the JCV-specific antibodies present in the serum or plasma specimens. After washing away the unbound antibodies, peroxidase-conjugated anti-human antibodies are added and bind to any captured JCV-specific antibodies. Excess conjugate is removed by washing. Enzyme substrate and chromagen are added, and the color is allowed to develop. After adding the Stop Reagent, the resultant color change is quantified by a spectrophotometric reading of OD. The percent inhibition is calculated to confirm presence of JCV-specific antibodies in the specimen. Specimens with a percent inhibition value that is greater than the specified cut-off are reported as positive for detectable JCV-specific antibodies, whereas specimens with percent inhibition values less than or equal to the cut-off are reported as negative for detectable JCV-specific antibodies.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

# a. Precision/Reproducibility:

# Reproducibility

The reproducibility of the assay was assessed using a sample panel consisting of four levels of sera, four levels of (EDTA) plasma samples, low and high positive controls. Three replicates of each panel member were tested on two runs a day for a total of five days at two external testing sites and one internal site. The four levels included a negative, low, indeterminate and moderate positive samples prepared in a serum and a plasma matrices. The indeterminate samples were tested simultaneously in the confirmation assay and the detection assay.

Table: Reproducibility   

<table><tr><td colspan="20" rowspan="1">JCV Gen-2 Validation Reproducibility Results</td></tr><tr><td colspan="1" rowspan="4">Jrrr</td><td colspan="1" rowspan="4">SdmeWMT</td><td colspan="1" rowspan="4">SampleName</td><td colspan="5" rowspan="1">QualitativeResults</td><td colspan="12" rowspan="1">Quantitative Results</td></tr><tr><td colspan="1" rowspan="3">ND1</td><td colspan="1" rowspan="3"></td><td colspan="1" rowspan="3">D</td><td colspan="1" rowspan="3"></td><td colspan="1" rowspan="3">DNVTotal</td><td colspan="1" rowspan="3">N</td><td colspan="1" rowspan="3">Mean</td><td colspan="10" rowspan="1">Variability Components</td></tr><tr><td colspan="2" rowspan="1">BetweenSites</td><td colspan="2" rowspan="1">BetweenDays</td><td colspan="2" rowspan="1">BetweenRuns/Operators</td><td colspan="2" rowspan="1">Within Assay(Repeatability)</td><td colspan="2" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td></tr><tr><td colspan="1" rowspan="1">D</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Cut-Off</td><td colspan="5" rowspan="1"></td><td colspan="1" rowspan="1">120</td><td colspan="1" rowspan="1">1.131</td><td colspan="1" rowspan="1">0.145</td><td colspan="1" rowspan="1">12.8</td><td colspan="1" rowspan="1">0.067</td><td colspan="1" rowspan="1">5.9</td><td colspan="1" rowspan="1">0.088</td><td colspan="1" rowspan="1">7.8</td><td colspan="1" rowspan="1">0.037</td><td colspan="1" rowspan="1">3.2</td><td colspan="1" rowspan="1">0.186</td><td colspan="1" rowspan="1">16.5</td></tr><tr><td colspan="1" rowspan="10">IUEEN</td><td colspan="1" rowspan="2">conus</td><td colspan="1" rowspan="1">NegativeCControl</td><td colspan="1" rowspan="1">89</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">89</td><td colspan="1" rowspan="1">0.102</td><td colspan="1" rowspan="1">0.010</td><td colspan="1" rowspan="1">9.5</td><td colspan="1" rowspan="1">0.007</td><td colspan="1" rowspan="1">7.1</td><td colspan="1" rowspan="1">0.010</td><td colspan="1" rowspan="1">9.7</td><td colspan="1" rowspan="1">0.006</td><td colspan="1" rowspan="1">6.1</td><td colspan="1" rowspan="1">0.017</td><td colspan="1" rowspan="1">16.5</td></tr><tr><td colspan="1" rowspan="1">PositiveControl</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">1.202</td><td colspan="1" rowspan="1">0.008</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">0.010</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">0.022</td><td colspan="1" rowspan="1">1.8</td><td colspan="1" rowspan="1">0.036</td><td colspan="1" rowspan="1">3.0</td><td colspan="1" rowspan="1">0.044</td><td colspan="1" rowspan="1">3.7</td></tr><tr><td colspan="1" rowspan="4">Brsnd</td><td colspan="1" rowspan="1">Indeterminate</td><td colspan="1" rowspan="1">−</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">b</td><td colspan="1" rowspan="1">−</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">0.270</td><td colspan="1" rowspan="1">0.010</td><td colspan="1" rowspan="1">3.7</td><td colspan="1" rowspan="1">0.009</td><td colspan="1" rowspan="1">3.4</td><td colspan="1" rowspan="1">0.011</td><td colspan="1" rowspan="1">4.2</td><td colspan="1" rowspan="1">0.014</td><td colspan="1" rowspan="1">5.1</td><td colspan="1" rowspan="1">0.023</td><td colspan="1" rowspan="1">8.3</td></tr><tr><td colspan="1" rowspan="1">Low positive</td><td colspan="1" rowspan="1">−</td><td colspan="1" rowspan="1">39</td><td colspan="1" rowspan="1">51</td><td colspan="1" rowspan="1">−</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">0.410</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.022</td><td colspan="1" rowspan="1">5.5</td><td colspan="1" rowspan="1">0.023</td><td colspan="1" rowspan="1">5.7</td><td colspan="1" rowspan="1">0.032</td><td colspan="1" rowspan="1">7.9</td></tr><tr><td colspan="1" rowspan="1">Mediumpositive</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">0.858</td><td colspan="1" rowspan="1">0.041</td><td colspan="1" rowspan="1">4.7</td><td colspan="1" rowspan="1">0.025</td><td colspan="1" rowspan="1">3.0</td><td colspan="1" rowspan="1">0.018</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">0.059</td><td colspan="1" rowspan="1">6.9</td><td colspan="1" rowspan="1">0.078</td><td colspan="1" rowspan="1">9.1</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">89</td><td colspan="1" rowspan="1">b</td><td colspan="1" rowspan="1">b</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">89</td><td colspan="1" rowspan="1">0.129</td><td colspan="1" rowspan="1">0.002</td><td colspan="1" rowspan="1">1.8</td><td colspan="1" rowspan="1">0.007</td><td colspan="1" rowspan="1">5.5</td><td colspan="1" rowspan="1">0.013</td><td colspan="1" rowspan="1">9.8</td><td colspan="1" rowspan="1">0.008</td><td colspan="1" rowspan="1">5.8</td><td colspan="1" rowspan="1">0.017</td><td colspan="1" rowspan="1">12.8</td></tr><tr><td colspan="1" rowspan="4">Snm</td><td colspan="1" rowspan="1">Indeterminate</td><td colspan="1" rowspan="1">−</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">b</td><td colspan="1" rowspan="1">−</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">0.283</td><td colspan="1" rowspan="1">0.012</td><td colspan="1" rowspan="1">4.3</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.011</td><td colspan="1" rowspan="1">3.9</td><td colspan="1" rowspan="1">0.018</td><td colspan="1" rowspan="1">6.3</td><td colspan="1" rowspan="1">0.024</td><td colspan="1" rowspan="1">8.5</td></tr><tr><td colspan="1" rowspan="1">Low positive</td><td colspan="1" rowspan="1">−</td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">72</td><td colspan="1" rowspan="1">−</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">0.422</td><td colspan="1" rowspan="1">0.004</td><td colspan="1" rowspan="1">0.9</td><td colspan="1" rowspan="1">0.004</td><td colspan="1" rowspan="1">1.1</td><td colspan="1" rowspan="1">0.018</td><td colspan="1" rowspan="1">4.2</td><td colspan="1" rowspan="1">0.013</td><td colspan="1" rowspan="1">3.1</td><td colspan="1" rowspan="1">0.023</td><td colspan="1" rowspan="1">5.4</td></tr><tr><td colspan="1" rowspan="1">Mediumpositive</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">1.055</td><td colspan="1" rowspan="1">0.048</td><td colspan="1" rowspan="1">4.5</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.041</td><td colspan="1" rowspan="1">3.9</td><td colspan="1" rowspan="1">0.045</td><td colspan="1" rowspan="1">4.3</td><td colspan="1" rowspan="1">0.078</td><td colspan="1" rowspan="1">7.4</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">84</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">b</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">86</td><td colspan="1" rowspan="1">0.109</td><td colspan="1" rowspan="1">0.024</td><td colspan="1" rowspan="1">22.3</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.018</td><td colspan="1" rowspan="1">16.5</td><td colspan="1" rowspan="1">0.013</td><td colspan="1" rowspan="1">11.7</td><td colspan="1" rowspan="1">0.033</td><td colspan="1" rowspan="1">30.1</td></tr><tr><td colspan="1" rowspan="4">Brermrr</td><td colspan="1" rowspan="4">SdmeeWk</td><td colspan="1" rowspan="4">SampleName</td><td colspan="5" rowspan="1">QualitativeResults</td><td colspan="12" rowspan="1">Quantitative Results</td></tr><tr><td colspan="1" rowspan="3">ND1</td><td colspan="1" rowspan="3"></td><td colspan="1" rowspan="3">D</td><td colspan="1" rowspan="3"></td><td colspan="1" rowspan="3">NVTotal</td><td colspan="1" rowspan="3">N</td><td colspan="1" rowspan="3">Mean</td><td colspan="10" rowspan="1">Variability Components</td></tr><tr><td colspan="2" rowspan="1">BetweenSits</td><td colspan="2" rowspan="1">BetweenDays</td><td colspan="2" rowspan="1">BetweenRuns/Operators</td><td colspan="2" rowspan="1">Within Assay(Repeatability)</td><td colspan="2" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td></tr><tr><td colspan="1" rowspan="2">Woqqi%</td><td colspan="1" rowspan="1">Prsnd</td><td colspan="1" rowspan="1">Indeterminate</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">77</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">88</td><td colspan="1" rowspan="1">51.05</td><td colspan="1" rowspan="1">2.006</td><td colspan="1" rowspan="1">3.9</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">3.648</td><td colspan="1" rowspan="1">7.1</td><td colspan="1" rowspan="1">3.357</td><td colspan="1" rowspan="1">6.6</td><td colspan="1" rowspan="1">5.348</td><td colspan="1" rowspan="1">10.5</td></tr><tr><td colspan="1" rowspan="1">Semm</td><td colspan="1" rowspan="1">Indeterminate</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">85</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">87</td><td colspan="1" rowspan="1">62.59</td><td colspan="1" rowspan="1">3.889</td><td colspan="1" rowspan="1">6.2</td><td colspan="1" rowspan="1">2.438</td><td colspan="1" rowspan="1">3.9</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">5.550</td><td colspan="1" rowspan="1">8.9</td><td colspan="1" rowspan="1">7.202</td><td colspan="1" rowspan="1">11.5</td></tr></table>

$\mathrm { N D } =$ Not Detected, $\mathrm { I } =$ Indeterminate, $\mathbf { D } =$ Detected, $\mathrm { N V } =$ Invalid

# Reproducibility around the Assay cut-off

In order to demonstrate precision near the assay cut-off, two contrived samples, one serum and one (EDTA) plasma samples were prepared to be near the lower cut-point of the assay. Each sample was diluted twenty times and tested in the detection assay and the confirmation assay. As depicted in the following table the $\% \mathrm { C V }$ was $\leq 2 . 6 \%$ .

Table: Reproducibility at the Limit of Detection   

<table><tr><td rowspan=2 colspan=1>SampleMatrix</td><td rowspan=1 colspan=6>Descriptive Statistics of Detection Assay(Index)</td><td rowspan=1 colspan=6>Descriptive Statistics of Confirmation Assay(%Inhibition)</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Min</td><td rowspan=1 colspan=1>Max</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Min</td><td rowspan=1 colspan=1>Max</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>0.34</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>61.66</td><td rowspan=1 colspan=1>66.97</td><td rowspan=1 colspan=1>65.11</td><td rowspan=1 colspan=1>1.43</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>19*</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>55.89</td><td rowspan=1 colspan=1>60.92</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>1.16</td><td rowspan=1 colspan=1>2</td></tr></table>

\*One replicate was Invalid

b. Linearity/assay reportable range: Not Applicable   
c. Traceability, Stability, Expected values (controls, calibrators, or methods): Not Applicable   
d. Detection limit:

Not Applicable

# e. Analytical specificity:

# Cross Reactivity

Cross reactivity was evaluated in a three part study conducted at an internal testing site.

I. The first study evaluated cross reactivity with commercially available human antibodies spiked into JCV negative serum and plasma as determined by the STRATIFY $\small \mathrm { J C V _ { \mathbb { R } } }$ DxSelect™ assay. The potentially cross reacting antibodies were spiked in at concentrations estimated to be approximately 2-4 times higher than the estimated detection limit of JCV antibody. Each antibody tested was not detected with the STRATIFY $\small \mathrm { J C V _ { \mathbb { R } } }$ DxSelect™ assay. There was no observed reactivity with the three potentially cross-reacting antibodies tested in this part of the study and the results are presented in the table below.

Table: Cross Reactivity - Part One – Spiked Antibodies   

<table><tr><td rowspan=2 colspan=1>Cross Reactant</td><td rowspan=2 colspan=1>Concentration</td><td rowspan=1 colspan=2>Agents Detected</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Plasma</td></tr><tr><td rowspan=1 colspan=1>Antibody to Escherichia coli</td><td rowspan=1 colspan=1>0.4 μg/mL</td><td rowspan=1 colspan=1>0/3</td><td rowspan=1 colspan=1>0/3</td></tr><tr><td rowspan=1 colspan=1>Antibody to Mycobacterium tuberculosis</td><td rowspan=1 colspan=1>0.4 μg/mL</td><td rowspan=1 colspan=1>0/3</td><td rowspan=1 colspan=1>0/3</td></tr><tr><td rowspan=1 colspan=1>Antibody to Pneumocystis jiroveci</td><td rowspan=1 colspan=1>Unquantified</td><td rowspan=1 colspan=1>0/3</td><td rowspan=1 colspan=1>0/3</td></tr></table>

II. The second part of the study included a panel consisting of a least twenty left over specimens that previously tested positive for each of the potential cross reacting antibodies. Each member of the panel was evaluated using the STRATIFY $\small \mathrm { J C V _ { \mathbb { R } } }$ DxSelect™ assay along with appropriate controls. The seroprevalence of JCV in the panel was compared to the expected seroprevalence of JCV in the normal population. If a group demonstrates a higher than expected seroprevalence of JCV (set as $> 7 0 \%$ for the purposes of this study) it may be an indicator of potential cross reactivity. Four groups of patients (C. pneumoniae, HIV, CMV and HSV 1) exhibited a positivity rate that was slightly above that observed in previously reported studies. The results suggest that these groups demonstrate potential cross reactivity.

Table: Cross Reactivity – Part Two – Sero-prevalence Comparison   

<table><tr><td colspan="1" rowspan="3">SampleMatrix</td><td colspan="1" rowspan="3">Cross Reactant</td><td colspan="1" rowspan="3">Total No.ofReplicatesorSamples</td><td colspan="3" rowspan="2">ScreeningResult Count(Based onIndex)</td><td colspan="3" rowspan="2">ConfirmationResult Count(Based on%Inhibition)</td><td colspan="4" rowspan="1">FinalInterpretation</td></tr><tr><td colspan="2" rowspan="1">Count</td><td colspan="2" rowspan="1">%</td></tr><tr><td colspan="1" rowspan="1">D</td><td colspan="1" rowspan="1">IND</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">NotTested</td><td colspan="1" rowspan="1">D</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">D</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">D</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Unknown</td><td colspan="1" rowspan="1">HIV</td><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">77.3</td><td colspan="1" rowspan="1">22.7</td></tr><tr><td colspan="1" rowspan="2">Serum</td><td colspan="1" rowspan="1">C. pneumoniae</td><td colspan="1" rowspan="1">48</td><td colspan="1" rowspan="1">35</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">43</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">77.1</td><td colspan="1" rowspan="1">22.9</td></tr><tr><td colspan="1" rowspan="1">C. trachomatis</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">60.0</td><td colspan="1" rowspan="1">40.0</td></tr><tr><td colspan="1" rowspan="10"></td><td colspan="1" rowspan="1">CMV</td><td colspan="1" rowspan="1">40</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">33</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">32</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">|80.0|</td><td colspan="1" rowspan="1">20.0</td></tr><tr><td colspan="1" rowspan="1">Candida</td><td colspan="1" rowspan="1">40</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">34</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">67.5</td><td colspan="1" rowspan="1">32.5</td></tr><tr><td colspan="1" rowspan="1">EBV</td><td colspan="1" rowspan="1">40</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">A</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">62.5</td><td colspan="1" rowspan="1">37.5</td></tr><tr><td colspan="1" rowspan="1">HSV 1</td><td colspan="1" rowspan="1">48</td><td colspan="1" rowspan="1">32</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">34</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">70.8</td><td colspan="1" rowspan="1">29.2</td></tr><tr><td colspan="1" rowspan="1">HSV 2</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">45.0</td><td colspan="1" rowspan="1">55.0</td></tr><tr><td colspan="1" rowspan="1">HHV6</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">−</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">55.0</td><td colspan="1" rowspan="1">45.0</td></tr><tr><td colspan="1" rowspan="1">Listeria</td><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">−</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">47.1</td><td colspan="1" rowspan="1">52.9</td></tr><tr><td colspan="1" rowspan="1">Mycoplasma</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">−</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">50.0</td><td colspan="1" rowspan="1">50.0</td></tr><tr><td colspan="1" rowspan="1">Treponemapallidum</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">68.4</td><td colspan="1" rowspan="1">31.6</td></tr><tr><td colspan="1" rowspan="1">VZV</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">65.0</td><td colspan="1" rowspan="1">35.0</td></tr><tr><td colspan="2" rowspan="1">All</td><td colspan="1" rowspan="1">334</td><td colspan="1" rowspan="1">208</td><td colspan="1" rowspan="1">48</td><td colspan="1" rowspan="1">78</td><td colspan="1" rowspan="1">286</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">33</td><td colspan="1" rowspan="1">223</td><td colspan="1" rowspan="1">111</td><td colspan="1" rowspan="1">66.8</td><td colspan="1" rowspan="1">33.2</td></tr></table>

$\mathrm { D } { = }$ Detected, $\mathrm { N D = }$ Not Detected, $\mathrm { I N D } =$ Indeterminate

III. The third part of the cross reactivity evaluation consisted of an evaluation of the potential cross reactivity with other polyoma viruses. This included a cross absorption study using BK virus like particles (VLP). A total of 40 clinical specimens that have previously tested positive for JCV antibodies in the STRATIFY $\small \mathrm { J C V _ { \widehat { \mathbb { R } } } }$ DxSelect™ assay were tested in a confirmation style assay using JC VLP and BK VLP. A control set consisted of samples spiked with JC VLP at the same concentration of VLP that is used in the confirmation assay. The test samples were with spiked with BK VLP at the same concentration. The tests samples would be considered to be cross reactive if the $\%$ change in signal between the unspiked sample and the sample spiked with BK VLP is $>$ $45 \%$ . The control set demonstrated $\%$ change in OD that was consistent with expectations. The test samples demonstrated $\%$ change in OD values due to BK VLP that ranged from -15 to $2 7 \%$ . No samples exhibited ${ > } 4 5 \%$ change in the OD signal when spiked with BK VLP, indicating that the assay does not cross react with BKV.

The potential cross reactivity with other human polyoma viruses was not evaluated. However, additional analysis of the structure of the VP1 protein of other polyoma viruses indicates that BKV and JCV are more closely related $7 9 . 4 \%$ similarity) than other polyoma virus such as Merkel Cell virus and WU virus and KI virus (30.8 to $50 . 8 \%$ similarity). Due to the differences in viral structure a similar experiment with other polyoma virus VLP was not conducted.

# Interferences

Potential interference due to endogenous substances was evaluated using a testing panel consisting of sera and plasma samples that exhibit JCV antibody values close to the assay cut-off. The samples are spiked with the potential interferent as compared to baseline of the same serum and plasma samples that did not contain the interferent.

The interferents were spiked at the highest possible endogenous level. For all of the potential interferents with the exception of $\gamma$ globulin; the observed differences in signal did not cause any changes in interpretation of the final result. A potentially interference is suspected if the $\%$ change from the baseline sample is $> 2 0 \%$ . Commercially available $\gamma$ globulin is produced using normal human serum containing IgG antibodies, due to the high seroprevalence of antibodies to JCV virus in the normal population this may explain the observed cross reactivity.

Table: Interference Summary – Signal Comparison to Baseline   

<table><tr><td rowspan=3 colspan=1>Substance Name</td><td rowspan=3 colspan=1>SubstanceConcentration</td><td rowspan=1 colspan=4>Plasma</td><td rowspan=1 colspan=4>Serum</td></tr><tr><td rowspan=1 colspan=3>Average Index</td><td rowspan=1 colspan=1>%Change</td><td rowspan=1 colspan=3>Average Index</td><td rowspan=2 colspan=1>%ChangefromBaseline</td></tr><tr><td rowspan=1 colspan=2>BaselineSample</td><td rowspan=1 colspan=1>InterferenceSample</td><td rowspan=1 colspan=1>fromBaseline</td><td rowspan=1 colspan=2>BaselineSample</td><td rowspan=1 colspan=1>InterferenceSample</td></tr><tr><td rowspan=1 colspan=1>Albumin</td><td rowspan=1 colspan=1>120 mg/mL</td><td rowspan=1 colspan=2>0.35</td><td rowspan=1 colspan=1>0.38</td><td rowspan=1 colspan=1>8.6</td><td rowspan=1 colspan=2>0.43</td><td rowspan=1 colspan=1>0.37</td><td rowspan=1 colspan=1>-14.0</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>0.03 mg/mL</td><td rowspan=1 colspan=2>0.40</td><td rowspan=1 colspan=1>0.42</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=2>0.42</td><td rowspan=1 colspan=1>0.44</td><td rowspan=1 colspan=1>4.8</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>0.2 mg/mL</td><td rowspan=1 colspan=2>0.33</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=2>0.42</td><td rowspan=1 colspan=1>0.38</td><td rowspan=1 colspan=1>-9.5</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>5 mg/mL</td><td rowspan=1 colspan=2>0.48</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>-16.7</td><td rowspan=1 colspan=2>0.46</td><td rowspan=1 colspan=1>0.44</td><td rowspan=1 colspan=1>-4.3</td></tr><tr><td rowspan=1 colspan=1>Gamma Globulin</td><td rowspan=1 colspan=1>60 mg/mL</td><td rowspan=1 colspan=2>0.38</td><td rowspan=1 colspan=1>3.54</td><td rowspan=1 colspan=1>831.6</td><td rowspan=1 colspan=2>0.41</td><td rowspan=1 colspan=1>3.52</td><td rowspan=1 colspan=1>758.5</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>110 mg/mL</td><td rowspan=2 colspan=2>0.36</td><td rowspan=1 colspan=1>0.41</td><td rowspan=1 colspan=1>13.5</td><td rowspan=2 colspan=2>0.44</td><td rowspan=1 colspan=1>0.46</td><td rowspan=1 colspan=1>5.0</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>165 mg/mL</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.38</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>0.39</td><td rowspan=1 colspan=1>-10.1</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>220 mg/mL</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>0.35</td><td rowspan=1 colspan=1>-2.4</td><td rowspan=1 colspan=2></td><td></td><td rowspan=1 colspan=1>0.37</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>10 mg/mL</td><td rowspan=1 colspan=2>0.36</td><td rowspan=1 colspan=1>0.35</td><td rowspan=1 colspan=1>-2.8</td><td rowspan=1 colspan=2>0.40</td><td rowspan=1 colspan=1>0.37</td><td rowspan=1 colspan=1>-7.5</td></tr></table>

Note: Three dilutions of Gamma Globulin stock solution exhibited Index values - 3.22, 3.57 and 3.40.

# $f .$ Assay cut-off:

To characterize antibody responses against infectious agents in humans, it is critical to have reference sera from both infected and non-infected individuals. However, JCV infection is clinically asymptomatic, thereby making it difficult to generally distinguish JCV infected from non-infected individuals. Even though about $20 \mathrm { - } 3 0 \%$ of JCV infected individuals shed viral DNA in the urine, JCV DNA is often not detected in the blood or urine of infected individuals, even when the infection results in the development of PML. There is no evidence that testing for JCV DNA in blood or urine can identify all JCV infected individuals, however, those who shed virus in the urine are confirmed to be infected with JCV.

Therefore, sera from viruric patients were used to establish the positive reference sera for the assay. The assay cut point was established from the distribution of the serological responses of samples collected from JCV viruric patients in the STRATIFY $\small \mathrm { J C V _ { \mathbb { R } } }$ DxSelect™ assay. The lower cut point for the detection assay was set at an index of 0.2 along with an upper cut point at 0.4, and inhibition cut point of the confirmation assay was set at $45 \%$ . The assay has an estimated false negative rate of $2 . 2 \%$ based on a negative JCV antibody results for 4 out of 184 serum samples collected from viruric patients in the STRATIFY-1 trial.

2. Comparison studies:

a. Method comparison with predicate device: See clinical studies

b. Matrix comparison:

A panel of 109 paired sera and (EDTA) plasma samples were evaluated in the STRATIFY $\small \mathrm { J C V _ { \mathbb { R } } }$ DxSelect™ assay. Of the total 109 pairs one pair was eliminated from the regression analysis because the result of the sera sample was invalid, of the remaining 108 pairs 7 pairs were qualitatively detected with OD values that exceeded the range of the spectrophotometer. These pairs of samples are included in the qualitative result comparison below, but eliminated from the regression analysis since an index value could not be calculated. Passing-Bablok regression analysis of the pairs of sera and plasma specimens demonstrates a slope of 1 with a $9 5 \%$ CI of (0.9928 to 1.0167)) and an intercept of 0 with a $9 5 \%$ CI of (-0.0068 to 0.0016). Analysis of the qualitative results yielded Positive Percent Agreement $= 9 6 . 7 \%$ (58/60), $9 5 \%$ CI: (88.6 to $9 9 . 1 \%$ ), and Negative Percent Agreement $= 9 7 . 9 \%$ (47/48), $9 5 \% C \mathrm { I }$ : (89.1 to $9 9 . 6 \%$ )

Table: Sample Matrix Comparison - Sera vs. Plasma Qualitative Results   

<table><tr><td rowspan=2 colspan=1>Final Plasma Result</td><td rowspan=1 colspan=3>Final Serum Result (Count)</td><td rowspan=2 colspan=1>All</td></tr><tr><td rowspan=1 colspan=1>ND</td><td rowspan=1 colspan=1>D</td><td rowspan=1 colspan=1>Invalid</td></tr><tr><td rowspan=1 colspan=1>ND</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>50</td></tr><tr><td rowspan=1 colspan=1>D</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>59</td></tr><tr><td rowspan=1 colspan=1>All</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>109</td></tr></table>

![](images/b7aacac434b0cea74eed6a5ca5d14326bac06b4796ca611a28b99fc721eb199a.jpg)  
Figure: Passing-Bablok Regression Analysis (Sera vs. Plasma)

3. Clinical studies:

a. Clinical Sensitivity: Not Applicable

b. Clinical specificity: Not Applicable

c. Other clinical supportive data (when a. and b. are not applicable):

There is an increased risk of PML in natalizumab treated multiple sclerosis (MS) and Crohn’s disease (CD) patients. Three risk factors for PML have been identified in MS and CD patient populations undergoing natalizumab treatment: natalizumab treatment duration, prior immunosuppressant use, and the presence of antibodies to JCV. Utilizing these three risk factors, sub-groups of patients can be identified with both higher and lower risk for PML. Please consult the current, locally available, prescribing or supplemental physician information for natalizumab for detailed information on the known risks associated with JCV serological status and the development of PML in natalizumab-treated patients. Patients with all three known risk factors have the highest risk for the development of PML. The risk stratification for PML in natalizumab treated patients who are positive for the presence of JCV antibodies is shown in the following table.

Table: Estimated Incidence of PML Stratified by Risk Factor   

<table><tr><td rowspan=2 colspan=1>NatalizumabExposure</td><td rowspan=1 colspan=2>JCV AntibodyPositive *</td></tr><tr><td rowspan=1 colspan=1>No Prior ImmunosuppressantUse</td><td rowspan=1 colspan=1>Prior Immunosuppressant Use</td></tr><tr><td rowspan=1 colspan=1>1-24 months</td><td rowspan=1 colspan=1>&lt;1/1,000</td><td rowspan=1 colspan=1>2/1,000</td></tr><tr><td rowspan=1 colspan=1>25-48 months</td><td rowspan=1 colspan=1>4/1,000</td><td rowspan=1 colspan=1>11/1,000</td></tr></table>

Notes: Based on postmarketing PML data and Natalizumab use data as of September 1, 2011. †Data beyond 4 years of treatment are limited. \*Risk in anti-JCV antibody positive patients was estimated based on the assumptions that $1 8 \%$ of Natalizumab-treated MS patients have a history of prior immunosuppressant treatment and that $5 5 \%$ of Natalizumab-treated MS patients are anti-JCV antibody positive.

# Clinical Performance (Comparative Agreement)

Because PML is an infrequent event in natalizumab-treated patients, data collected from both clinical trial and post-marketing reports of confirmed cases of PML were used to assess the clinical performance of the STRATIFY $\small \mathrm { J C V _ { \mathbb { R } } }$ DxSelect™ assay for PML risk stratification. A clinical plan was developed for collection of serum samples obtained from natalizumabtreated patients prior to the onset of PML for JCV antibody testing. A total of 31 available serum samples from confirmed PML patients collected at least 6 months prior to clinical diagnosis of PML were tested for JCV antibody status using the STRATIFY $\small \mathrm { J C V _ { \mathbb { R } } }$ DxSelect™ assay. In addition to the pre-PML samples, 1330 Samples from MS patients were tested by the STRATIFY $\small \mathrm { J C V _ { \mathbb { R } } }$ DxSelect™ assay. A total of 707 patients receiving treatment tested positive for antibodies to JCV using the test, and the positivity rate was estimated to be $5 8 . 7 \%$ (414/707) with a $9 5 \%$ CI of $5 4 . 9 \%$ to $6 2 . 1 \%$ . An assay is statistically informative if the percentage of positive results in patients with the disease of interest is higher than the percentage of positive results in the population at risk. The $100 \%$ JCV antibody positivity demonstrated in the 31 natalizumab-treated PML patients prior to PML diagnosis was significantly different than the $5 8 . 7 \%$ JCV antibody positivity in the MS population, and represents an approximately 2-fold increased risk of PML compared to the PML incidence in the overall natalizumab-treated population.

In prior clinical studies for natalizumab the risk of developing PML was estimated using statistical modeling. The relative risk for patients who have received natalizumab for at least 18 months is shown in the table below. Risk was calculated based on statistical modeling with an assumption that there is one hypothetical PML case with a negative test result (38 PML cases: 37 positive and 1 hypothetical negative) and an assumption that the study has 13,227 patients.

Table: Estimated incidence of PML by JCV serological status   

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Number withPML</td><td rowspan=1 colspan=1>Numberwithout PML</td><td rowspan=1 colspan=1>Total numberpatients treated</td></tr><tr><td rowspan=2 colspan=2>JCV SerologicalStatus</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>7,229</td><td rowspan=1 colspan=1>7,266</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1*</td><td rowspan=1 colspan=1>5,960</td><td rowspan=1 colspan=1>5,961</td></tr><tr><td rowspan=1 colspan=3>Total</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>13,189</td><td rowspan=1 colspan=1>13,227</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>cYanmaGYellowb</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=3>Risk of PML (per 1,000) treated with ≥18 months for Positive result</td><td rowspan=1 colspan=3>5.0995% CI: 3.70 to 7.01</td></tr><tr><td rowspan=1 colspan=3>Risk of PML (per 1,000) treated with ≥18 months for Negative result</td><td rowspan=1 colspan=3>0.1795% CI: 0.03 to 0.95</td></tr><tr><td rowspan=1 colspan=3>Relative risk</td><td rowspan=1 colspan=3>30.495% CI: 5.3 to 437.4</td></tr></table>

\*For the negative result, a hypothetical case was assumed in order to allow for calculation of the point estimate.

The studies demonstrated that the positivity rate for JCV antibodies is not dependant upon prior IS use or the duration of natalizumab treatment. The results of the STRATIFY $\small \mathrm { J C V _ { \mathbb { R } } }$ DxSelect™ assay can be used along with other established PML risk factors, of prior IS use and natalizumab treatment duration, to stratify an individuals risk for PML, please refer to Table 1 and to the prescribing information for additional risk estimates.

# Performance with pre-PML samples.

The STRATIFY $\small \mathrm { J C V _ { \mathbb { R } } }$ DxSelect™ assay was compared to an FDA cleared assay (STRATIFY $\mathbf { J } { \mathbf { C V } } ^ { \mathbf { T M } }$ Antibody ELISA) using serum samples obtained from PML patients at least 6 months prior to PML diagnosis. Because PML is an infrequent event in natalizumabtreated patients, data collected from both clinical trial and post-marketing reports of confirmed cases of PML were used to assess the clinical performance of the STRATIFY $\small \mathrm { J C V _ { \mathbb { R } } }$ DxSelect™ assay for PML risk stratification. Thirty-one available serum samples from confirmed PML patients collected at least 6 months prior to clinical diagnosis of PML were tested at one internal testing site for JCV antibody status using the STRATIFY $\small \mathrm { J C V _ { \mathbb { R } } }$ DxSelect™ assay and the validated laboratory methodology. The sample set demonstrated $100 \%$ (31/31) positive agreement $9 5 \%$ CI: $8 9 . 0 \%$ to $100 \%$ ) with the validated assay.

# Performance with archived clinical specimens

Two groups of prospectively collected and archived clinical samples obtained from the STRATIFY-2 and the AFFIRM clinical studies were used to assess the performance of the STRATIFY $\small \mathrm { J C V _ { \mathbb { R } } }$ DxSelect™ assay compared to the validated laboratory methodology used in the STRATIFY-2 and AFFIRM clinical studies. One group consisted of patients who were receiving natalizumab, the other group of patients had not received natalizumab therapy (and were considering receiving natalizumab). The samples were blinded and randomly distributed to two external testing sites and one internal testing site. The data was analyzed for each group separately. Results for the two individual groups are presented in the tables below. The Positive and Negative Percent Agreement are shown in the table below.

Table: Agreement for Clinical Samples – Patients Receiving Natalizumab   

<table><tr><td rowspan=2 colspan=1>STRATIFY JCV DxSelectTM</td><td rowspan=1 colspan=2>Predicate Device</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>385</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>414</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>281</td><td rowspan=1 colspan=1>293</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>397</td><td rowspan=1 colspan=1>310</td><td rowspan=1 colspan=1>707</td></tr><tr><td rowspan=1 colspan=1>Positive Percent Agreement(PPA)</td><td rowspan=1 colspan=3>97.0% (385/397)95% CI: 94.8 to 98.3%</td></tr><tr><td rowspan=1 colspan=1>Negative Percent Agreement(NPA)</td><td rowspan=1 colspan=3>90.6% (281/310)95% CI: 86.9 to 93.4%</td></tr></table>

Table: Agreement for Clinical Samples - Patients Considering Natalizumab   

<table><tr><td rowspan=2 colspan=1>STRATIFY JCV DxSelectTM</td><td rowspan=1 colspan=2>Predicate device</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>326</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>350</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>268</td><td rowspan=1 colspan=1>273</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>331</td><td rowspan=1 colspan=1>292</td><td rowspan=1 colspan=1>623</td></tr><tr><td rowspan=1 colspan=1>Positive %Agreement (PPA)</td><td rowspan=1 colspan=3>98.5% (326/331)95% CI: 96.5 to 99.4%</td></tr><tr><td rowspan=1 colspan=1>Negative %Agreement (NPA)</td><td rowspan=1 colspan=3>91.8% (268/292)95% CI: 88.1 to 94.4%</td></tr></table>

4. Clinical cut-off:

Not Applicable

# 5. Expected values/Reference range:

The STRATIFY $\small \mathrm { J C V _ { \mathbb { R } } }$ DxSelect™ assay been used to evaluate JCV antibody positivity rate in serum and plasma samples from a geographically diverse cohort of $1 3 3 0 ~ \mathrm { M S }$ patients. The cohort was comprised from MS patients from clinical trials including a completed Phase 3 clinical study of natalizumab in MS patients (AFFIRM C-1801), an ongoing study to evaluate seroprevalence in the MS population (STRATIFY-2 [101JC402). The clinical characteristics for the MS patients within each study are shown in the following table. The age and gender distribution of the MS cohort tested with the STRATIFY $\small \mathrm { J C V _ { \mathbb { R } } }$ DxSelect™ are similar to the age and gender distribution of MS patients treated with natalizumab in the post-marketing setting. JCV antibody positivity rate in the MS cohort was $5 5 \mathrm { - } 5 9 \%$ . JCV antibody positivity rate was shown to increase with age and was lower in women compared to men, consistent with what has been reported in the literature in healthy adults using similar assay methodologies.

Seroprevalence data was evaluated for each study. The observed seroprevalence using the STRATIFY $\small \mathrm { J C V _ { \mathbb { R } } }$ DxSelect™ assay was $59 \%$ (467/792) in the STRATIFY-2 study and $5 5 \%$ (296/538) in the AFFIRM Study. These seroprevalence values are consistent with the seroprevalence values observed during the clinical studies, when the relationship between JCV serological status and PML development were described. Additionally the STRATIFY $\operatorname { J C V } @ $ DxSelect™ assay demonstrated $100 \%$ concordance with 31 pre-PML samples.

# Table: Demographic Data and JCV Antibody Prevalence for MS Patients

<table><tr><td rowspan=1 colspan=1>cYanmaGYellowb</td><td rowspan=1 colspan=1>AFFIRM(N=538)</td><td rowspan=1 colspan=1>STRATIFY-2(N=792)</td></tr><tr><td rowspan=1 colspan=1>Age (years)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>•Range</td><td rowspan=1 colspan=1>18-50</td><td rowspan=1 colspan=1>19-78</td></tr><tr><td rowspan=1 colspan=1>•Mean</td><td rowspan=1 colspan=1>35.8</td><td rowspan=1 colspan=1>46.4</td></tr><tr><td rowspan=1 colspan=1>•Median</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>46</td></tr><tr><td rowspan=1 colspan=1>Gender (%)*</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Male</td><td rowspan=1 colspan=1>173/538 (32.2%)</td><td rowspan=1 colspan=1>202/792 (25.5%)</td></tr><tr><td rowspan=1 colspan=1>Female</td><td rowspan=1 colspan=1>365/538 (67.8%)</td><td rowspan=1 colspan=1>590/792 (74.5%)</td></tr><tr><td rowspan=1 colspan=1>Geography</td><td rowspan=1 colspan=1>North America andEU/Rest of World</td><td rowspan=1 colspan=1>US</td></tr><tr><td rowspan=1 colspan=1>JCV Antibody Positivity Rate(95% CI)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>• % JCV Antibody Positive</td><td rowspan=1 colspan=1>297/538 (55.2%)(51.0 to 59.4)</td><td rowspan=1 colspan=1>467/792 (59.0%)(55.5 to 62.3)</td></tr><tr><td rowspan=1 colspan=1>% JCV Antibody Negative</td><td rowspan=1 colspan=1>241/538 (44.8%)(40.6 to 49.0)</td><td rowspan=1 colspan=1>325/792 (41.0%)(37.7 to 44.5)</td></tr></table>

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

1. The submitted information in this premarket notification is complete and supports a substantial equivalence decision